IP Library Granted Patent US 12692221
Granted Patent B2
US 12692221 · App. 19/212,649 · Granted Jul 28, 2026

5-methoxymethyl and 5-hydroxymethyl phenethylamines

Inventor: David E. Nichols (Chapel Hill, NC)
Assignee: 2A Biosciences, Inc.
C07C217/60A61K31/137A61P25/00C07C215/52C07C217/48C07C2601/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692221
App. No.
19/212,649
Granted
Jul 28, 2026
Kind
B2
Abstract

Novel compounds, such as phenethylamines having a 5-methoxymethyl or 5-hydroxymethyl substituent, are provided. In some aspects, pharmaceutical compositions comprising the compounds, methods of synthesizing the compounds, and methods of using such compounds, including their administration to subjects, are also provided. In some aspects, useful features of the compounds include neuromodulatory and/or anti-inflammatory activity, for example via activation of serotonin receptors. In some further aspects, the compounds are useful as therapeutic agents for treating medical conditions, such as psychiatric disorders and inflammatory conditions, including inflammation and inflammatory diseases and disorders.

Claims (10)

1 . A compound having the following structure:

or a pharmaceutically acceptable salt, hydrate, solvate, or isotopic derivative thereof.

2 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , and a pharmaceutically acceptable carrier, diluent, or excipient.

3 . The pharmaceutical composition of claim 2 , wherein the composition is suitable for oral, buccal, sublingual, intranasal, injectable, subcutaneous, intravenous, topical, transdermal, ocular, ophthalmic, intraocular, or periocular administration.

4 . The pharmaceutical composition of claim 2 , wherein the composition is in a unit dosage form.

5 . The pharmaceutical composition of claim 4 , comprising the compound in a total amount of between about 0.01 mg and about 100 mg.

6 . The pharmaceutical composition of claim 3 , formulated for injectable administration.

7 . The pharmaceutical composition of claim 3 , formulated for topical administration.

8 . The pharmaceutical composition of claim 3 , formulated for ophthalmic administration.

9 . The pharmaceutical composition of claim 3 , formulated for intraocular administration.